Program-At-A-Glance


DAY 1 FRIDAY, NOVEMBER 1, 2013
7:30 AM
4:00 PM
Registration
8:00 AM -
9:00 AM
Breakfast
8:30 AM -
9:30 AM
Diabetes, Obesity and Hypertension: Economic Implications in African Americans
Speaker: James R Gavin, III, MD, PhD
Upon completion of this topic, participants should be able to:
  • Identify the scope of these metabolic risks by region, gender, and SES
  • Design treatment programs using new and established treatments, with a focus on reducing outcomes
  • Recommend policy changes to insure greater treatment access to the highest risk members of affected populations
  • Identify barriers to more effective treatments for these conditions in African Americans
9:30 AM -
10:00 AM
Pathophysiological Approaches to Management of Type 2 Diabetes
9:30 AM -
10:00 AM
Pathophysiological Approaches to Management of Type 2 Diabetes
Speaker: Kwame Osei, MD
10:30 AM
11:30 AM
Product Theater I
Speaker: Oliseyenum Nwose / SPONSORED: DSI
10:30 AM
1:00 PM
EXHIBIT HOURS
11:30 PM -
12:30 AM
Lunch
1:00 PM
2:00 PM
DPPIV Inhibitors Role in Management of Diabetes in African Americans
Speaker: Anthony Cannon, MD
Upon completion of this topic, participants should be able to:
  • Review the clinical importance of Incretin Based Therapies in the Management of High Risk Patients with T2DM.
  • Update the ADA/EA.
  • SD position statement on the treatment of T2DM, a patient focus approach.
  • Review and compare the efficacy and safety of different DPP4-I agents.
  • Incretin Based Therapies and Cardiovascular Outcomes in T2DM.
2:00 PM
3:00 PM
SGLT2 Inhibitors: Importance in Management of Type 2 Diabetes in African Americans
Speaker: James W. Reed, MD
3:00 PM
5:00 PM
EXHIBIT HOURS
3:30 PM
4:30 PM
Product Theater II
LOCATION: Hancock
5:00 PM
6:00 PM
Reception


DAY 2: SATURDAY, NOVEMBER 2, 2013
8:00 AM
3:00 PM
Registration
8:00 AM
8:30 AM
Breakfast
8:30 AM -
9:30 AM
New Insulin Therapies: Advantages over Old Insulins
Speaker: Kathleen Dungan, MD
Upon completion of this topic, participants should be able to:
  • Describe important racial/ethnic disparities with insulin therapy
  • Review the efficacy and limitations of older insulins
  • Understand the role for newer insulins
  • Highlight new insulins in late clinical trials
9:30 AM
11:00 AM
EXHIBIT HOURS
9:45 AM
10:45 AM
Product TheaterIII
LOCATION: Hancock
11:30 AM
12:45 PM
Combination of Insulin and Oral Antidiabetic Agents: New Approaches and Paradigms
Speaker: Kyaw Soe, MD
Upon completion of this topic, participants should be able to:
  • Understand the evidence based use of combination therapy of insulin and oral anti-diabetic agents
  • Identify the clinical experience and outcome of combination therapy of insulin and oral anti-diabetic agents
12:00 PM
1:45 PM
EXHIBIT HOURS
12:45 PM
1:45 PM
Lunch
1:45 PM
3:00 PM
Diabetes and Hypertension: Management of Cardiovascular Risk Factors in African Americans: Where are We? (JNC VII, ISHIB Consensus Statement, ADA What Is a Practicing Physician to Do?)
Moderator: Brent Egan, MD

Speakers:
John M. Flack, MD, MPH
Jackson T. Wright Jr., MD, PhD

Upon completion of this topic, participants should be able to:
  • Explain the published data in regards to the benefits and risks of hypertension treatment in persons with diabetes mellitus
  • Identify the approach to minimizing risk during the treatment of hypertension in persons with diabetes mellitus
  • Understand the prevalence of diabetes and pressure-sensitive diabetes complications such as retinopathy and vision-threatening retinopathy and stroke in African Americans with diabetes
  • Provide a framework for reconciling conflicting or absent clinical trial data in a manner that leads to a belief in a blood pressure target below which you as a practitioner are committed to keep your high risk patients with diabetes below